Successful management of chylous ascites after living donor liver transplantation with somatostatin

2007 ◽  
Vol 0 (0) ◽  
pp. 070908015728002-??? ◽  
Author(s):  
Hideki Ijichi ◽  
Yuji Soejima ◽  
Akinobu Taketomi ◽  
Tomoharu Yoshizumi ◽  
Hideaki Uchiyama ◽  
...  
2013 ◽  
Vol 97 (4) ◽  
pp. 360-362 ◽  
Author(s):  
Hiroaki Shiba ◽  
Shigeki Wakiyama ◽  
Takeshi Gocho ◽  
Yuichi Ishida ◽  
Takeyuki Misawa ◽  
...  

Abstract A 46-year-old man underwent living-donor liver transplantation and splenectomy for primary biliary cirrhosis. On postoperative day 22, cloudiness of ascites increased, and triglyceride concentration in ascites was as high as 1046 mg/dL. With a diagnosis of chylous ascites, total parenteral nutrition was started. Nine days after starting total parenteral nutrition, cloudiness of ascites decreased, and triglycerides in ascites decreased to 93 mg/dL. Oral intake was restarted, and the patient was discharged on postoperative day 46. Chylous ascites is a rare complication after living-donor liver transplantation for which total parenteral nutrition may be useful.


2012 ◽  
Vol 73 (7) ◽  
pp. 1770-1773
Author(s):  
Takuya YOICHI ◽  
Masayuki OTSUKA ◽  
Fumio KIMURA ◽  
Hiroaki SHIMIZU ◽  
Hiroyuki YOSHIDOME ◽  
...  

Swiss Surgery ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 227-236 ◽  
Author(s):  
Majno ◽  
Mentha ◽  
Berney ◽  
Bühler ◽  
Giostra ◽  
...  

Living donor liver transplantation is a relatively new procedure in which the right side of the liver is harvested in a healthy donor and transplanted into a recipient. After the first case in 1994, over 3000 cases have been done worldwide. This review summarizes the reasons why the procedure is needed, describes its main technical aspects, highlights the boundaries in which it can be done safely, summarizes the current experience worldwide and describes the main points of the program in our unit. We argue that living-donor transplantation is a viable alternative to a long time on the waiting list for several patients, and it can be performed safely and successfully provided that all precautions are undertaken to minimize the risks in the donor and to increase the chances of a good outcome in the recipients. If these prerequisites are met, and within the framework of a structured multidisciplinary program, we believe that living-donor liver transplantation should be funded by health insurances as a recognized therapeutic option.


Sign in / Sign up

Export Citation Format

Share Document